menu
    • menu
    [{"orgOrder":0,"company":"Edenbridge Pharmaceuticals","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent to Supply Edenbridge Pharmaceuticals with a Patient-Focused Fast-Dissolve Zydis\u00ae Formulation of Glycopyrrolate Intended for Use as Adjunctive Therapy in the Treatment of Patients with Peptic Ulcer","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Agreement","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Edenbridge Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Edenbridge Pharmaceuticals \/ Edenbridge Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Edenbridge Pharmaceuticals \/ Edenbridge Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Edenbridge Pharmaceuticals

    Menu

    Edenbridge Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Edenbridge Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed

                            Edenbridge Pharmaceuticals

                            U.S.A arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glycopyrronium Bromide

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Recipient : Catalent Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Catalent to Supply Edenbridge Pharmaceuticals with a Patient-Focused Fast-Dissolve Zydis® Formulation of Glyc...

                            Details : Both companies signed a commercial supply agreement, for a novel formulation of glycopyrrolate (Dartisla) using Catalent’s proprietary Zydis® orally disintegrating tablet delivery technology intended for use as adjunctive therapy in the treatment of p...

                            Brand Name : Dartisla

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 10, 2021

                            Lead Product(s) : Glycopyrronium Bromide

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Recipient : Catalent Pharma Solutions

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth